$SGMT News
Last published 2d ago
- 2d agoSGMTGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - SAGIMET BIOSCIENCES INCEarnings Call TranscriptsInnovation Conference, this is 2026, so I'm really pleased to have Sagemet Biosciences with us. So Dave Appel, CEO, and Andreas Grauer, the Chief Medical Officer. You know, this ist a company that we've really enjoyed wa
- 2d agoSGMTGuggenheim 3rd Annual Healthcare Innovation Conference - SAGIMET BIOSCIENCES INCEarnings Call TranscriptsInnovation Conference, this is 2026, so I'm really pleased to have Sagemet Biosciences with us. So Dave Appel, CEO, and Andreas Grauer, the Chief Medical Officer. You know, this ist a company that we've really enjoyed wa
- 1w agoSGMTSagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis
- 2w agoSGMTSagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe AcneGlobeNewswireWith first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal
- 1mo agoSGMTSagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology ConferenceGlobeNewswireDenifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% IGA success, 72% reduction in total lesions, and 77% reduction in inflammatory lesions, and
- 2mo agoSGMTSagimet Biosciences Announces Participation in Two Upcoming Investor ConferencesGlobeNewswireFOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 2mo agoSGMTSagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026GlobeNewswireAll clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) --
- 2mo agoSGMTSagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 3mo agoSGMTSagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult PatientsGlobeNewswireFOSTER CITY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 3mo agoSGMTCG 46TH ANNUAL GROWTH CONFERENCE - SAGIMET BIOSCIENCES INCEarnings Call TranscriptsHi, good afternoon, everyone. My name is Edward Nash, Senior Biotech Analyst here at Canaccord Genuity. I'm joined here by the management team of Sagemet Biosciences. With us from Sagemat, we have Dave Heppel, who's the
- 3mo agoSGMTCG 46TH ANNUAL GROWTH CONFERENCE - SAGIMET BIOSCIENCES INCEarnings Call TranscriptsHi, good afternoon, everyone. My name is Edward Nash, Senior Biotech Analyst here at Canaccord Genuity. I'm joined here by the management team of Sagemet Biosciences. With us from Sagemat, we have Dave Heppel, who's the
- 3mo agoSGMTSagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswirePhase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Secured
- 3mo agoSGMTSagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth ConferenceGlobeNewswireFOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 4mo agoSGMTSagimet Biosciences Joins the Russell 2000® and Russell 3000® IndexesGlobeNewswireSAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 4mo agoSGMTSagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 5mo agoSGMTSagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASHGlobeNewswirePhase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid reductions in
- 6mo agoSGMTSagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQGlobeNewswireSAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 6mo agoSGMTSagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireSecured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase
- 6mo agoSGMTSagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in ChicagoGlobeNewswirePre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of
- 6mo agoSGMTSagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common StockGlobeNewswireSAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 6mo agoSGMTSagimet Biosciences Provides Strategic and Corporate UpdatesGlobeNewswirePhase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Further MASH
- 6mo agoOMERSGMTSagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerGlobeNewswireSAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 7mo agoSGMTSagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 8mo agoSGMTSagimet Biosciences Announces Participation in Three Upcoming Investor ConferencesGlobeNewswireSAN MATEO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 9mo agoSGMTSagimet Biosciences Announces Participation in Two Upcoming Investor ConferencesGlobeNewswireSAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 9mo agoSGMTSagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe AcneGlobeNewswireSAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 9mo agoSGMTAscletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for AcnePR NewswireAscletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating...
- 9mo agoSGMTBiotech Veteran and Virologist Joins CancerVax as Senior Scientific AdvisorGlobeNewswireLehi, Utah, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, January 27, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body's immune system to treat cancer,
- 10mo agoSGMTSagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom CombinationGlobeNewswireThe combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combination in F4 MASH
- 10mo agoSGMTSagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination ProgramGlobeNewswireLicense Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applicationsCollaboration supports
- 11mo agoSGMTSagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products AdministrationGlobeNewswireSAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 11mo agoSGMTAscletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne TreatmentPR NewswireAscletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class,...
- 11mo agoSGMTSagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 11mo agoSGMTSagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare ConferenceGlobeNewswireSAN MATEO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 12mo agoSGMTSagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewswirePhase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing
- 1y agoSGMTSagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025GlobeNewswireA secondary analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients as measured by artificial intelligence (AI) digital pathology In a
- 1y agoSGMTDenifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology ConferenceGlobeNewswireDenifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announced completion of
- 1y agoSGMTSagimet Biosciences Announces Participation in Three Upcoming Investor ConferencesGlobeNewswireSAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and
- 1y agoSGMTSagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025GlobeNewswireSAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 1y agoSGMTSagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom CombinationGlobeNewswireDosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated in the first
- 1y agoSGMTSagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech WeekGlobeNewswireSAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and
- 1y agoSGMTAscletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025PR NewswireAscletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the oral presentation of the Phase III study results of denifanstat (ASC40) for...
- 1y agoSGMTPositive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner AscletisGlobeNewswireDenifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, for development
- 1y agoSGMTSagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development SummitGlobeNewswireSAN MATEO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and
- 1y agoSGMTSagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoSGMTSagimet Biosciences to Participate in Two Upcoming Investor ConferencesGlobeNewswireSAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 1y agoSGMTSagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewswireDenifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial of FASN inhibitor
- 1y agoSGMTSagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewswireSAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 1y agoSGMTSagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025GlobeNewswireSAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 1y agoSGMTSagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner AscletisGlobeNewswireDenifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet